Jobs
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.
We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.
GRAIL is headquartered in the bay area of California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.
For more information, please visit grail.com
This is a customer-focused position that requires a “market builder” mindset. A successful GGC1 acts with urgency and passion to engage physicians and their staff to think differently about cancer screening and change the way they practice, integrating MCED technology into their office workflow, and consistently offering it to appropriate patients with the goal to identify more cancers sooner.
GRAIL is the first company in the world to bring MCED technology to patients and clinicians - this is a rare opportunity in one's career!
The GGC1 role is an in-person selling role, with the expectation that candidates spend the majority of their time (>85%) making in-person visits to targeted physician practices, planning and supporting events, and executing on Company initiatives.
This is a field-based role located in your city and state, currently covering the following territory: St. Louis, East St. Louis, Belleville, Cape Girardeau and surrounding areas. While you will primarily operate in the field, travel to a GRAIL office or other locations may be required to support business needs.
We’re building a world-class team to take on one of healthcare’s most important challenges. Are you ready to join us?
Total Views
0
Apply Clicks
0
Weekly mock applicants
0
Bookmarks
0
Similar jobs

Continuous Improvement Leader (DBSL)
Danaher · Hebron, Kentucky, United States

Aviseur Technique – Électrique (Manic 3)-1
GE Vernova · Remote

Upstream Buyer Planner
Schneider Electric · Oxford, Ohio

Medicare Sales Field Agent - CarePlus Lake/Marion/Sumter
Humana · 5 Locations

Operations Specialist with Swedish
Marsh McLennan · Warsaw - Prosta
About Grail

Grail
Series CGRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
201-500
Employees
Menlo Park
Headquarters
$3.2B
Valuation
Reviews
3.9
10 reviews
Work-life balance
3.8
Compensation
3.5
Culture
4.2
Career
3.0
Management
3.2
72%
Recommend to a friend
Pros
Good work-life balance
Supportive team and management
Innovative and challenging projects
Cons
Heavy workload and overwhelming at times
Limited career advancement opportunities
Management and communication issues
Salary Ranges
135 data points
Junior/L3
Mid/L4
Senior/L5
Director
Junior/L3 · Operations Engineer 2
1 reports
$103,500
total per year
Base
$90,000
Stock
-
Bonus
-
$103,500
$103,500
Interview experience
4 interviews
Difficulty
2.8
/ 5
Duration
14-28 weeks
Experience
Positive 25%
Neutral 75%
Negative 0%
Interview process
1
Application Review
2
Recruiter Screen
3
Technical Phone Screen
4
Onsite/Virtual Interviews
5
Team Matching
6
Offer
Common questions
Technical Knowledge
Behavioral/STAR
Past Experience
Coding/Algorithm
News & Buzz
GRAIL (NASDAQ: GRAL) outlines CEO transition, director elections in 2026 proxy - Stock Titan
Stock Titan
News
·
6d ago
My Grail Everyday Watch Gets the Perfect Summer Revamp - Gear Patrol
Gear Patrol
News
·
6d ago
Lilly's $2.25B bet chases genetic medicine's 'holy grail' - FirstWord Pharma
FirstWord Pharma
News
·
6d ago
Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’ - BioSpace
BioSpace
News
·
6d ago